Author

Z. Flinchbaugh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:non-human primate· 5 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Assay:metagenomics· 1

Frequent Co-Authors

A. Cook· 5 shared H. Andersen· 4 shared L. Pessaint· 4 shared A. Van Ry· 3 shared M. G. Lewis· 3 shared A. Chandrashekar· 2 shared A. Choi· 2 shared A. Dodson· 2 shared

Activity by Year

2021-2021 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

A. Cook

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1

A. To, T. A. S. Wong, M. M. Lieberman, K. S. Thompson, L. Pessaint, J. Greenhouse, N. Daham, A. Cook, B. Narvaez, Z. Flinchbaugh, A. Van Ry, J. Yalley-Ogunro, H. Andersen, C.-Y. Lai, O. Donini, A. T. Lehrer

A recombinant subunit vaccine with CoVaccine HT adjuvant provides durable, broad neutralizing antibodies against SARS-CoV-2 VOCs in macaques, outperforming natural infection in protection and viral load reduction.

bioRxiv · Sep 24, 2021Immunology

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates

M. Gebre, S. Rauch, N. Roth, J. Yu, A. Chandrashekar, N. Mercado, X. He, J. Liu, K. McMahan, A. Martinot, T. Giffin, D. Hope, S. Patel, D. Sellers, O. Sanborn, , D. H. Barouch

This study compares two mRNA SARS-CoV-2 vaccines in nonhuman primates, showing that CV2CoV, with optimized non-coding regions, provides better immune responses and protection than CVnCoV.

bioRxiv · Aug 13, 2021 · PreprintImmunology

Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates

K. S. Corbett, M. Gagne, D. Wagner, S. O'Connell, S. R. Narpala, D. R. Flebbe, S. F. Andrew, R. L. Davis, B. Flynn, T. S. Johnston, C. Stringham, L. Lai, D. Valentin, A. Van Ry, Z. Flinchbaugh, , A Pekosz

mRNA-1273 boosted nonhuman primates show increased neutralizing antibody responses and protection against SARS-CoV-2 beta variant infection.

bioRxiv · Aug 11, 2021 · PreprintImmunology

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates

N. C. Dalvie, L. H. Tostanoski, S. A. Rodriguez-Aponte, K. Kaur, S. Bajoria, O. Kumru, A. J. Martinot, A. Chandrashekar, K. McMahan, N. B. Mercado, J. Yu, A. Chang, V. M. Giffin, F. Nampanya, S. Patel, , D. H. Barouch

This paper describes a protein subunit vaccine candidate produced in yeast that protects non-human primates against SARS-CoV-2, showing high neutralizing antibody titers and reduced viral loads after challenge.

bioRxiv · Jul 13, 2021 · PreprintImmunology

Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

K. S. Corbett, A. Werner, S. O'Connell, M. Gagne, L. Lai, J. Moliva, B. Flynn, A. Choi, M. Koch, K. E. Foulds, S. Andrew, D. Flebbe, E. Lamb, S. T. Nurmukhambetova, S. Provost, , M. Suthar

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

bioRxiv · May 21, 2021 · PreprintImmunology